We have developed a modular scaffold for preparing high-affinity, homo-multivalent inhibitors of the prostate-specific membrane antigen (PSMA) for imaging and therapy of prostate cancer (PCa). Our system contains a lysine-based (∝-, ε-) dialkyne residue for incorporating a PSMA binding Lys-Glu urea motif exploiting click chemistry and a second lysine residue for subsequent modification with an imaging or therapeutic moiety. The utility of the multivalent scaffold was examined by synthesizing bivalent compounds 2 and 3 and comparing them with the monovalent analog 1. 
INTRODUCTION
Prostate cancer (PCa) will kill an estimated 33,720 men in the US alone this year [1] . The integral membrane protein prostate-specific membrane antigen (PSMA) is becoming increasingly recognized as a viable target for imaging and therapy of prostate and other forms of cancer [2] [3] [4] . PSMA is significantly over-expressed in PCa and metastases, particularly with respect to the castrationresistant form [5] . Accordingly, PSMA may provide a negative prognostic indicator for PCa -enabling distinction of indolent from aggressive disease. Imaging PSMA has also provided insight into androgen signaling [6] and information on response to taxane therapy [7] .
Recently we and others have demonstrated successful PSMA-targeted radionuclide imaging in experimental models of PCa using cysteine-glutamate or lysine-glutamate ureas. With those agents the radionuclide ( 11 C, 125 I, 18 F) is attached to the cysteine or lysine moiety via a small prosthetic group [8] [9] [10] [11] [12] . For large molecular fragments, such as radiometal ( 99m Tc, 68 Ga,
111
In) chelators, organic fluorescent molecules, and nanoparticles, we have determined that a linking moiety of at least 20 Å (long-linker) between the large molecule and the lysine moiety facilitates productive binding [13] [14] [15] . We have also developed a PSMA-targeted, dual (radionuclide and optical) modality imaging platform that enables sequential, dual modality imaging [16] . As an extension of this program, here we prepare bivalent ligands with a view to improving the affinity and pharmacokinetic properties of the urea class of PSMA inhibitors. The strategy we employ can be generalized to multivalent compounds. Because they present multiple copies of the pharmacophore, multivalent ligands can bind to receptors with high avidity and affinity, thereby serving as powerful inhibitors [17, 18] . Various approaches have been reported to exploit multivalent scaffolds for the construction of molecular imaging probes [19] [20] [21] [22] . However, the chemistry used to produce them can become complicated, even more so when a bifunctional chelator must be attached to a separately multimerized construct to introduce a radionuclide, for example, for imaging. Although, the concept of multimerization for PSMA targeted, near-infrared imaging agents has been proffered for in vitro cell binding studies [22] , to our knowledge a multivalent PSMA-binding agent has not yet been shown to image PSMA successfully in vivo. Here we use click chemistry [23, 24] with our long-linker platform as a convenient route to build a modular scaffold for multimeric presentation of PSMA targeting species and demonstrate the enhanced ability of the bivalent form, over the corresponding monomer, to target PSMA in vivo.
RESULTS AND DISCUSSION
Our modular multivalent scaffold contains a lysinebased (∝-, ε-) dialkyne residue for incorporating PSMA binding Lys-Glu urea moieties exploiting click chemistry [23, 24] and a second lysine residue for subsequent modification with an imaging and/or therapeutic nuclide or a cytotoxic ligand for tumor cell kill. The divalent agent was anticipated to have a prolonged biological half-life and enhanced specific binding and retention in tissues expressing PSMA. To evaluate the anticipated multivalent effect, a versatile Lys-Glu-urea-based azide intermediate (1) was prepared to serve as a monovalent control Chart 1: www.impactjournals.com/oncotarget compound (Chart 1) against the bivalent compound 2 and the DOTA-chelated bivalent urea analog, 3 to examine the effect of adding a chelating agent to bivalent urea 2. Compounds 2 and 3 were conveniently prepared by employing simple peptide coupling and click chemistry [23, 24] as shown in Scheme 1.
Starting with commercially available FmocLys(Boc)-Wang resin and using standard Fmoc-based solid phase peptide chemistry, 1 -4 were prepared in suitable yields. In brief, Fmoc-Lys(Boc)-Wang was treated with 20% piperidine/DMF to remove the Fmoc group followed by coupling with commercially available Fmoc-Lys(Fmoc)-OH in the presence of benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) and N,N-diisopropylethylamine (DIEA). In the next step, a microwave-assisted coupling reaction was performed using propiolic acid in presence of 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) in DMF to improve the yield and purity of the desired product. Finally, 4 was isolated in ~ 40% yield after treating the resin with a cocktail of TFA/H 2 O/TES (95/2.5/2.5) at ambient temperature for 0.5 h. Compound 4, a Lys-based (∝-, ε-) dialkyne peptide, served as the key intermediate to introduce multimerization. Copper catalyzed click chemistry was employed using the azide intermediate 1 and dialkyne peptide 4 to produce multivalent compound 2 in moderate yield after purification by high-performance liquid chromatography (HPLC). Compound 3 was prepared by coupling the free amine of the lysine residue of 2 with the N-hydroxysuccinimide ester of DOTAtris-acid using DIEA as a base in DMSO at ambient temperature for 4 h. Compound 3 was purified by HPLC and obtained in ~15% overall yield. Compound 3 was labeled with 111 In at 95°C in 0.3 M NaOAc buffer within 20 min in ~70 -90% yield and specific radioactivity of ~ 8.4 -204.4 GB/µmol. PSMA inhibition constant (K i ) values for 1 -3 were determined using a fluorescence-based PSMA inhibition assay [8] . The data are presented in Table 1 . As revealed from the K i values, the binding affinity was found to increase 5-fold from monovalent 1 to bivalent 2. Interestingly, there was an 11-fold increase to the DOTA-chelated bivalent compound 3 compared to 1 leading to subnanomolar binding affinity for 3. Under the same experimental conditions, the K i value of the known PSMA inhibitor ZJ-43 [25] high inhibitory potency of 3. The inhibition curves of 1 -3, which are expressed with respect to the amount of glutamate released from hydrolysis of the natural PSMA substrate, N-acetylaspartylglutamate (NAAG), are shown in Figure 1 . A structurally similar triazole version of 1, compound 6 (Chart 1, Table 1 ) was also tested for PSMA inhibitory activity in vitro in a previous experiment [34] . The K i value of 6 was 0.92 nM in that experiment, in which ZJ-43 demonstrated a K i value of 0.35 (95% CI, 0.2 -0.6 nM), suggesting that the affinity of 6 is likely significantly less than the bivalent compounds 2 or 3. Compound 6 was radiolabeled with 99m Tc and its biological properties were tested in vivo [34] . A manuscript describing those biological data is in preparation. Figure 2 shows the pharmacokinetic behavior of [ as well as to specific uptake from the expression of PSMA in mouse kidneys [27] . Clearance of radioactivity from kidney and non-target tissues was more rapid than from target tumor such that by 48 h post-injection (p.i.) a high tumor/background ratio was observed ( Figure 2 [10, 13, 14, 16, 22, [28] [29] [30] [31] 
18 F]DCFBC [15] , which has recently been administered to human subjects [30] . We also compared the in vivo properties of the bivalent compound [ Table 3 ). The synthesis and characterization of 5 [32] At/ 131 I for radiotherapy. Other fluorophores/chelating agents/ radiometals/nonmetals/cytotoxic agent combinations can also be envisioned using this approach. Another significant aspect of the multivalent scaffold is that it will enable us to generate systematically at least 4-and 8-valent urea compounds from the lysine-diamine intermediate 4 upon repeated conjugation of 4 with Fmoc-Lys(Fmoc-OH) to produce a lysine-based multimeric urea dendron.
METHODS

Chemistry
Solvents and chemicals obtained from commercial sources were of analytical grade or better and used without further purification. Indium (III) nitrate, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ), triethylsilane (Et 3 SiH), N,Ndiisopropylethylamine (DIEA) and triethylamine (TEA) were purchased from Sigma-Aldrich (Saint Louis, MO). All other chemicals were purchased from Thermo Fisher Scientific (Pittsburgh, PA) unless otherwise specified. Analytical thin-layer chromatography (TLC) was performed using Aldrich aluminum-backed 0.2 mm silica gel Z19, 329-1 plates and visualized by ultraviolet light (254 nm), I 2 and 1% ninhydrin in EtOH. Flash chromatography was performed using MP SiliTech 32-63 D 60Å silica gel purchased from Bodman (Aston, PA). All experiments were performed in duplicate or triplicate to ensure reproducibility. A z i d o -5 , 1 3 , 2 0 -t r i o x o -4 , 6 , 1 2 , 2 1 -tetraazahexacosane-1,3,7, 
( 3 S , 7 S ) -2 6 -
22-tetracarboxylic acid, Compound 1
This compound was prepared following our previous report [34] . Briefly, commercially available Boc-Lys(Azide)-OH was treated with a solution of TFA/ CH 2 Cl 2 (1:1) at ambient temperature for 4h to remove the Boc group. After solvent removal, the crude product, H-Lys(azide)-OH, was directly used for the next step. To a solution of H-Lys(azide)-OH (50 mg, 0.29 mmol in 500 µL DMSO) was added NHS-ester of Lys-Glu urea (24 mg, 0.43 mmol in 500 µL DMSO) [16] and DIEA (100 µL) and left at ambient temperature for 4 h. Solvent was evaporated to dryness and the residue was dissolved in water and purified by HPLC (Method 1). Retention time 
6-amino-2-(2,6-dipropiolamidohexanamido)hexanoic acid, 4
Compound 4 was synthesized using standard Fmoc mediated solid phase peptide synthesis. Formation and masking of free amines was assessed using the Kaiser test [35] . Washing the resin with 3 mL DMF three times, 1 minute each, before and after each step was performed until liberation of the final product from the resin. All steps were performed at ambient temperature unless otherwise mentioned. After being swollen by 3 mL DMF, Fmoc-Lys-(Boc)-Wang resin (500 mg, 0.18 mM) was deprotected by settling with 3 mL 20% piperidine in DMF x 2, 5 min each time, before coupling with Fmoc-Lys-(Fmoc)-OH (318 mg, 0.54 mM) preactivated with DIEA (124 uL, 0.72 mM) and PyBOP (280 mg, 0.54 mM in 3 mL DMF). The last coupling was performed twice, 30 minutes in duration each time. The Fmoc groups were removed using 3 mL 20% piperidine in DMF x 2, 5 min each time. Coupling with propiolic acid (75 mg, 1.08 mM) was achieved using a solution of EEDQ (268 mg, 1.08 mM) as a coupling reagent in 2 mL DMF and accelerated via exposure to microwave irradiation x 5, 30 sec each time. Ten percent of the maximum power of a standard kitchen microwave was enough to achieve complete coupling as indicated by a negative Kaiser test [35] . Cleavage of 4 from the resin was achieved by settling with 2 mL TFA/H 2 O/TES (95/2.5/2.5) mixture for 30 min followed by washing twice with 2 mL 100% TFA. The collected fractions were evaporated under vacuum after which the concentrated product was purified using a Sep-Pak® Vac 35 cc tC 18 tube (Waters, WAT043350). Compound 4 was eluted with 5% acetonitrile in water (0.1 % TFA). HPLC: Method 2, R t : 10 min. ( 1 -( ( 5 -a m i n o -1 -c a r b o x y p e n t y l )  amino)-1-oxo-6-(1-((7S)-1,3,7,22-tetracarboxy-5,13,20-trioxo-4,6,12,21-tetraazahexacosan-2 6 -y l ) -1 H -1 , 2 , 3 -t r i a z o l e -4 -c a r b o x a m i d o )  hexan-2-yl)carbamoyl)-1H-1,2,3-triazol-5-yl)-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22 tetracarboxylic acid, PSMA-targeted homobivalent compound 2
Compound 1 (49 mg, 76.7 µM) and 4 (0.5 eq, 14.5 mg, 38.3 µM) were dissolved in 1 mL H 2 O/t-BuOH (1/1). To that solution, sodium ascorbate (6 mg, 30 µM) and Cu(OAc)2 (3 mg, 15 µM) were added consecutively, the mixture was purged with N 2 gas and stirred at ambient temperature overnight. Compound 2 was purified using C 18 SepPak® Vac 2 g column through which the product was successfully eluted using 70/30 water/acetonitrile (0.1% TFA). Compound 2 was further purified by HPLC (Method 1). R t : 13. To a solution of 2 (4 mg, 2.44 µM in 500 µL DMF) was added DOTA-NHS ester (1.5 mg, 3.66 µM in 500 µL DML) and DIEA (50 µL) and left at ambient temperature for 4h. Solvent was removed under vacuum and the residue was dissolved in 2 mL water and was purified using HPLC Method 3. 
Biological Studies
PSMA Inhibition
The PSMA inhibitory activities of 1 -3 and [
113/115
In]3 were determined using a fluorescence-based assay according to a previously reported procedure [8] . Briefly, lysates of LNCaP cell extracts (25 µL) were incubated with the inhibitor (12.5 µL) in the presence of 4 µM NAAG (12.5 µL) for 120 min. The amount of glutamate released upon hydrolysis of NAAG was measured by incubating with a working solution (50 µL) of the Amplex Red Glutamic Acid Kit (Life Technologies, Grand Island, NY) for 60 min. Fluorescence was measured with a VICTOR3V multilabel plate reader (Perkin Elmer Inc., Waltham, MA) with excitation at 530 nm and emission at 560 nm. Inhibition curves were determined using semi-log plots and IC 50 values were determined at the concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate. Enzyme inhibitory constants (K i values) were generated using the Cheng-Prusoff conversion [36] . Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA).
Cell Culture and Animal Models
Sublines of the androgen independent PC-3 human prostate cancer xenograft originally derived from an advanced androgen independent bone metastasis were used. Those sublines have been modified to express high (PC-3 PIP) and low (PC-3 flu) PSMA levels and were generously provided by Dr. Warren Heston (Cleveland Clinic). Both PSMA-expressing (PC-3 PIP) and nonexpressing (PC-3 flu) prostate cancer cell lines were grown in RPMI 1640 medium (Mediatech Inc., Manassas, VA) containing 10% fetal bovine serum (FBS) (Sigma Aldrich, St.Louis, MO) and 1% Pen-Strep (Mediatech Inc., Manassas, VA) as previously described [12] . All cell cultures were maintained at 5% carbon dioxide (CO 2 ), at 37°C in a humidified incubator. Animal studies were carried out in full compliance with the regulations of the Johns Hopkins Animal Care and Use Committee. Six-to eight-week-old male, non-obese diabetic (NOD)/ severe-combined immunodeficient (SCID) mice (Johns Hopkins Animal Core, Baltimore, MD) were implanted subcutaneously (s.c.) with PC-3 PIP (PSMA+) and PC-3 flu (PSMA-) cells (2 x 10 6 in 100 µL of Matrigel) at the forward right and left flanks, respectively. Mice were imaged or used in biodistribution assays when the xenografts reached 5 to 7 mm in diameter.
Gamma Scintigraphy and SPECT/CT
Compound [ 111
In]3 was imaged using male SCID mice. Xenograft models were generated as described above. Mice were anesthetized using 1% isoflurane in oxygen flowing at 0.6 L/min prior to and during radiochemical injection. Mice were injected via the tail vein with approximately 1.2 mCi (44.4 MBq) of [ 111 In]3 formulated in 100 μL of saline, pH 7. After allowing for 30 -60 min of radiochemical uptake, anesthetized mice were placed on the scanner gantry and secured with medical tape while the anesthetic flow was increased to 0.8 L/min. The body temperature of the mice was maintained by covering them with several layers of absorbent, disposable pads and illumination with a dissection lamp during scanning. Single-pinhole median-energy (PHME) collimators with an aperture size of 1.0 mm, and stepwise rotation for 64 projection angles in a full 360° rotation, 40 s increments were used for SPECT imaging. The radius of rotation (ROR) was set at 7 cm, which provided a field of view of 7.5 cm to cover the mouse body from head to bladder. A CT scan was performed prior to scintigraphy for both anatomical co-registration and attenuation correction. A total of 512 projections were acquired in a 2 min continuous rotation mode covering a full 360° rotation. Data were reconstructed and fused using commercial software from the vendor (Gamma Medica-Ideas, Northridge, CA), which includes a 2D-OSEM algorithm. Data were analyzed and volume-rendered images were generated using AMIDE software (SourceForge, http:// amide.sourceforge.net/). In]3. Four mice were sacrificed by cervical dislocation at 2 and 24 h p.i. The heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, and PC-3 PIP and flu tumors were quickly removed. A 0.1 mL sample of blood was also collected. Each organ was weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Compugamma CS, Pharmacia/ LKB Nuclear, Inc., Gaithersburg, MD). The percentage injected dose per gram of tissue (%ID/g) was calculated by comparison with a standard dilution of the initial dose. All measurements were corrected for radioactive decay.
Biodistribution
